Page 9 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 9
Chapter 7
Chapter 8
Chapter 9
Chapter 10 Addendum
Performance of 89Zr-labeled-rituximab-PET as an 141 imaging biomarker to assess CD20 targeting: a pilot
study in patients with relapsed/refractory diffuse large
B cell lymphoma.
PLoS ONE. 2017;12:e0169828.
Assessment of target-mediated uptake with immuno- 157 PET: analysis of a phase I clinical trial with an anti-
CD44 antibody.
EJNMMI Res. 2018; 8:6.
89Zr-immuno-PET: towards a non-invasive clinical tool 175 to measure target engagement of therapeutic antibodies in-vivo.
J Nucl Med. 2019; Epub ahead of print
Summary and discussion 195
211 Nederlandse samenvatting 213 Acknowledgements / Dankwoord 222 Curriculum vitae 224 List of publications 225 List of abbreviations 230
